KRAS and malignant colon neoplasm: Proteomic screening identified that p38γ specifically interacts with heat shock protein 90 α (HSP90α) in KRAS-mutated but not KRAS wild-type colon cancer cells, and phosphorylates HSP90α at S595, thus preventing mutant KRAS protein from degradation and conferring sensitivity of KRAS mutant colon cancer cells to HSP90 inhibitor 17-alllylaminogeldanamycin (17-AAG) [58].